Ranjan Malhotra, MD
Ophthalmology · Saint Louis, MONPI 1396743555
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $605,866 of the $809,089 with a category attached, or 74.9%. 38 manufacturers reported payments, led by AbbVie at 25.3% of the total. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,706 payments — averaging $474.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$205K
- Bausch & Lomb Americas Inc.$191K
- Tarsus Pharmaceuticals, Inc.$80K
- Harrow Eye, LLC$47K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$47K
- Biotissue Holdings Inc.$36K
- plus $204K from 32 others
Across 35 payments — averaging $4653.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec Production LLC$72K
- Sun Pharmaceutical Industries Inc.$50K
- NEW World Medical,inc.$13K
- Aerie Pharmaceuticals, Inc.$11K
- Alcon Research LLC$9K
- Ivantis, Inc$6K
- plus $2K from 1 others
What the payments were for
- Consulting fees$102,35813%
- Speaking & faculty fees$605,86675%
- Travel & lodging$42,4045%
- Food & beverage$58,2647%
- Education$1050%
- Gifts$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$148,600
- MIEBO$142,887
- DURYSTA$115,798
- XDEMVY$76,773
- VYZULTA$47,893
- VEVYE$45,832
- Rocklatan$26,354
- VUITY$25,183
- Prokera$24,887
- AmnioGraft$24,887
- CEQUA$22,183
- Rhopressa$20,394
- LOTEMAX SM$19,394
- RESTASIS$18,740
- EYSUVIS$16,789
- Flarex$16,007
- RESTASIS MULTIDOSE$14,880
- INVELTYS$12,250
- TYRVAYA$11,483
- AmnioGuard$11,281
How this compares
$809,089 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 278 | $226,644 |
| RestasisCyclosporine | 181 | $218,327 |
| XiidraLifitegrast | 153 | $168,554 |
| LumiganBimatoprost | 261 | $134,992 |
| XdemvyLotilaner | 61 | $117,303 |
| VyzultaLatanoprostene Bunod | 133 | $57,620 |
| VevyeCyclosporine | 41 | $36,050 |
| Cyclosporine | 26 | $17,815 |
| CombiganBrimonidine Tartrate/Timolol | 48 | $16,192 |
| Lotemax SmLoteprednol Etabonate | 27 | $9,695 |
| ZirganGanciclovir | 11 | $4,989 |
| FlarexFluorometholone Acetate | 37 | $4,833 |
| ValacyclovirValacyclovir Hcl | 80 | $4,296 |
| RhopressaNetarsudil Mesylate | 14 | $4,128 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $3,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta, Zirgan | $190,968 | $457,807575 claims |
| AbbVieRestasis, Lumigan, Combigan | $204,701 | $369,510490 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $79,974 | $117,30361 claims |
| Harrow Eye, LLCVevye | $46,677 | $36,05041 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $46,640 | $9,69527 claims |
| Eyevance Pharmaceuticals LLCFlarex | $26,833 | $4,83337 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $27,036 | $4,12814 claims |
| AlconSimbrinza | $4,035 | $3,69211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Navin TekwaniSaint Louis$34K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
- Sean EdelsteinSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.